A novel long noncoding RNA PILRLS promote proliferation through TCL1A by activing MDM2 in Retroperitoneal liposarcoma
Metrics: PDF 1947 views | HTML 1921 views | ?
Yebo Shao1,*, Yong Zhang1,*, Yingyong Hou2,*, Hanxing Tong1, Rongyuan Zhuang3, Zhengbiao Ji4, Binliang Wang5, Yuhong Zhou3, Weiqi Lu1
1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Medical Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
3Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China
5Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
*These authors contributed equally to this work
Weiqi Lu, email: [email protected]
Yuhong Zhou, email: [email protected]
Keywords: LncRNA-PILRLS, proliferation, MDM2, P53 signaling pathway, retroperitoneal liposarcoma
Received: September 20, 2016 Accepted: December 27, 2016 Published: January 25, 2017
It is becoming evident that lncRNAs may be an important class of pervasive genes involved in carcinogenesis and metastasis. However, the biological and molecular mechanisms of lncRNAs in retroperitoneal liposarcoma have never been reported. In our study, we found a novel lncRNA PILRLS (Proliferation Interacting LncRNA in Retroperitoneal Liposarcoma), which as an oncogene significantly overexpressed in retroperitoneal liposarcoma. Functions of PILRLS on tumor progression both in vitro and in vivo have verified in this study which PILRLS knockdown significantly inhibited cell proliferation and colony formation. RNA pull-down assay found PILRLS can specific binding with TCL1A which also regulate the expression level of TCL1A. Our work for the first time demonstrated PILRLS can activating the MDM2 by binding with TCL1A which suppress the P53 pathway to promote the unlimited growth of retroperitoneal Liposarcoma cells. It suggests that PILRLS may be an important targets for retroperitoneal liposarcoma therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.